{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:17:01Z","timestamp":1781345821792,"version":"3.54.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (&amp;gt;65 years of age) and this population is expected to increase in the following years. A simplified geriatric assessment based on a careful evaluation of the fitness status and comorbidities is essential to choose the correct intensity of treatment. Fit older patients can benefit from a standard immunochemotherapy, while unfit\/frail patients frequently need reduced doses or substitution of particular agents with less toxic ones. This review focuses on new therapies (e.g., polatuzumab vedotin, tafasitamab, bispecific antibodies) that have indicated promising results in relapsed\/refractory patients, particularly in cases not eligible to transplant. Some of these new drugs have been tested as single agents or in combinations as first-line treatment, aiming to improve the outcome of the traditional chemotherapy. If preliminary efficacy and safety data are confirmed in future clinical trials, a chemo-free immunotherapic approach could become an alternative option to offer a curative treatment even in frail patients.<\/jats:p>","DOI":"10.3389\/fonc.2023.1214026","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T07:33:05Z","timestamp":1688369585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["New treatment options in elderly patients with Diffuse Large B-cell Lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Annalisa","family":"Arcari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"B1","unstructured":"Cancer stat facts: NHL-diffuse Large b-cell lymphoma (DLBCL) 2015-2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large b-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the united states and Western Europe: population-level projections for 2020-2025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk Lymph"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated b-cell like subtype among de novo diffuse large b-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large b-cell lymphoma: the perspective elderly project of the fondazione italiana linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7360","article-title":"Succeeding in breaking the r-CHOP ceiling in DLBCL: learning from negative trials","volume":"35","author":"Goy","year":"2017","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center b-cell diffuse large b-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus r-CHOP versus placebo plus r-CHOP in previously untreated patients with ABC-type diffuse large b-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large b-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson cancer center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0320-9","article-title":"Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large b-cell lymphoma","volume":"33","author":"Dodero","year":"2019","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large b-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large b-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse b-cell non-hodgkin\u2019s lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European society of cardiology in collaboration with the international cardio-oncology society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp544","article-title":"Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large b-cell lymphoma (DLBCL): results from the phase II EURO18 trial","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3730","article-title":"R-COMP versus r-CHOP as first-line therapy for diffuse large b-cell lymphoma in patients \u2265 60 years: results of a randomized phase 2 study from the Spanish GELTAMO group","volume":"10","author":"Sancho","year":"2021","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2764","article-title":"Nonpegylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity","volume":"38","author":"Rigacci","year":"2020","journal-title":"Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103377","article-title":"Efficacy of r-COMP in comparison to r-CHOP in patients with DLBCL: a systematic review and single-arm metanalysis","volume":"163","author":"Visco","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large b-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2768-x","article-title":"R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large b cell lymphoma","volume":"95","author":"Laribi","year":"2016","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281407","article-title":"Diffuse large b-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the elderly project of the fondazione italiana linfomi (FIL)","volume":"108","author":"Tucci","year":"2023","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large b-cell non-Hodgkin lymphoma: a phase II multicenter study of the fondazione italiana linfomi","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"key":"B28","first-page":"305","article-title":"Lenalidomide and rituximab (ReRi) as front-line chemo-free therapy for elderly frail patients with diffuse large b-cell lymphoma. a phase II study of the fondazione italiana linfomi","volume-title":"Blood","author":"Gini","year":"2021"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large b-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.025","article-title":"High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large b cell lymphoma: a nationwide retrospective study","volume":"20","author":"Chihara","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw653","article-title":"Treatment outcomes for older patients with relapsed\/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY","volume":"28","author":"Davison","year":"2017","journal-title":"12 trial. Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.029","article-title":"Outcomes of autologous hematopoietic cell transplantation in older patients with diffuse large b-cell lymphoma","volume":"28","author":"Munshi","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR-T cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large b-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large b-cell lymphoma: results from the US lymphoma CAR-T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large b cell lymphoma in the united states","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large b-cell lymphoma above the age of 70 years compared to younger patients \u2013 a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.019","article-title":"Transplant-ineligible but chimeric antigen receptor T-cell eligible: a real and relevant population","volume":"175","author":"Vic","year":"2022","journal-title":"Eur J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large b-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large b-cell lymphoma: primary analysis of phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2022","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive b-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large b-cell lymphoma who are not candidates for high-dose therapy","volume":"98","author":"Mounier","year":"2013","journal-title":"A phase II Lymhoma Study Assoc trial. Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1106536","article-title":"Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large b-cell lymphoma patients: an Italian retrospective multicenter study","volume":"57","author":"Arcari","year":"2016","journal-title":"Leuk Lymph"},{"key":"B47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Pettengel","year":"2012","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2019-124886","article-title":"Mechanistic characterization of tafasitamab-mediated antibody-dependent cellular phagocytosis alone or in combination with lenalidomide","volume":"134","author":"Mougiakakos","year":"2019","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large b-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the phase II l-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large b-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large b-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005953","article-title":"Results of a united kingdom real-worl study of polatuzumab vedotin, bendamustine, and rituximab for relapsed\/refractory DLBCL","volume":"6","author":"Northend","year":"2022","journal-title":"Blood Adv"},{"key":"B58","article-title":"Tafasitamab and lenalidomide in relapsed\/refractory large b cell lymphoma (R\/R LBCL): real world outcomes in a multicenter retrospective study","volume-title":"Blood","author":"Qualls","year":"2022"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large b-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell.engaging antibody, in relapsed or refractory large b-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory b-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"B62","article-title":"Odronextamab in patients with relapsed\/refractory (r\/r) diffuse large b-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2","volume-title":"Blood","author":"Kim","year":"2022"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00597","article-title":"Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large b-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B64","article-title":"Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly\/unfit patients with previously untreated diffuse large b-cell lymphoma","volume-title":"Blood","author":"Olszewski","year":"2022"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1214026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T07:33:09Z","timestamp":1688369589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1214026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":64,"alternative-id":["10.3389\/fonc.2023.1214026"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1214026","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"article-number":"1214026"}}